Anti-Daratumumab Idiotypic Recombinant Monoclonal

Daratumumab is a human monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of multiple myeloma. Daratumumab binds to CD38 on multiple myeloma cells and induces cell death through a number of different mechanisms including antibody-dependent cellular cytotoxicity. Sequence of Daratumumab: (Heavy chain) EVQLLESGGG LVQPGGSLRL SCAVSGFTFN SFAMSWVRQA PGKGLEWVSA ISGSGGGTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYFCAKDK ILWFGEPVFD YWGQGTLVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK (Light chain) EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPPTFGQ GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC (Disulfide bridge: H22-H96, H149-H205, H225-L214, H231-H'231, H234-H'234, H266-H326, H372-H430, H'22-H'96, H'149-H'205, H'225-L'214, H'266-H'326, H'372-H'430, L23-L88, L134-L194, L'23-L'88, L'134, L'194)